发布时间：2026-04-15 10:09
INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. announced today the initiation of Phase 1 clinical trial for SBE303. SBE303 is Samsung Bioepis’s first novel antibody-drug conjugate (ADC) candidate engineered to bind to Nectin-4, an adhesion protein that is specifically expressed in tumor cells, including urothelial cancer, lung cancer, and breast cancer.1The Phase 1 clinical trial for SBE303 is an openlabel, multi-center, firstinhuman trial to evaluate the safety, tolerability and efficacy of SBE303 in participants with advanced refractory solid tumors. More information on this study is available atclinicaltrials.gov(NCT07524348).





About Samsung Bioepis Co., Ltd.

Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to becom
=*=*=*=*=*=
当前为第1/2页
下一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页